Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Varsha Revankar

Internal Medicine Clarkston, MI Medical Doctor

NPI 1124196548 CMS profile 142376

5625 Water Tower Pl Ste 200, Ste 110, Clarkston, MI 48346

Open in the dashboard

General payments

$7,711

513 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Varsha Revankar of Clarkston, MI is reported in the CMS Open Payments database as having received $7,711 across 513 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $613 36
2023 General $1,553 95
2022 General $1,524 102
2021 General $1,516 109
2020 General $959 66
2019 General $1,547 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Varsha Revankar
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Varsha Revankar were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Varsha Revankar Internal Medicine median Middle half National median
2019 $1,547 $159 $48–$570 $163
2020 $959 $119 $33–$402 $114
2021 $1,516 $135 $37–$521 $132
2022 $1,524 $141 $42–$496 $149
2023 $1,553 $149 $45–$519 $160
2024 $613 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novo Nordisk Inc $1,532 119 payments
  2. AstraZeneca Pharmaceuticals LP $909 57 payments
  3. Lilly USA, LLC $747 52 payments
  4. Pfizer Inc. $669 46 payments
  5. GlaxoSmithKline, LLC. $616 45 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $456 19 payments
  7. Amgen Inc. $389 25 payments
  8. Merck Sharp & Dohme Corporation $345 27 payments
  9. AbbVie, Inc. $345 20 payments
  10. Sanofi-Aventis U.S. LLC $254 16 payments
  11. Other $1,449 87 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $7,711 513 payments
Products named General payments · program years 2019–2024
  1. Ozempic $1,019 87 payments
  2. RYBELSUS $756 71 payments
  3. FARXIGA $453 28 payments
  4. TRELEGY ELLIPTA $382 27 payments
  5. JARDIANCE Diabetes $354 27 payments
  6. TRULICITY $350 24 payments
  7. STEGLATRO $345 27 payments
  8. MOUNJARO $331 20 payments
  9. JANUVIA $300 25 payments
  10. JARDIANCE Diabetes $258 8 payments
  11. Other $7,063 464 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 96 drugs

Part D claims

5,048

Median for Internal Medicine: 777

Drug cost

$549,196

Median for Internal Medicine: $73,373

Branded share of claims

21.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 86 $106,633
Trulicity Dulaglutide Brand 55 $99,110
Jardiance Empagliflozin Brand 67 $88,232
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 36 $37,626
Farxiga Dapagliflozin Propanediol Brand 19 $30,288
Januvia Sitagliptin Phosphate Brand 21 $27,521
Repatha Sureclick Evolocumab Brand 33 $23,332
Mounjaro Tirzepatide Brand 13 $17,418
Eliquis Apixaban Brand 28 $16,205
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 20 $13,394

The 10 drugs with the highest cost, of 96 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$35,849

Medicare's payments for the services billed

Medicare patients

191

Average age 76

Services billed

683

144 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 36%
Ischemic heart disease 31%
Osteoporosis 21%
Chronic kidney disease 19%
Depression 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $71
$71 — —
MOUNJARO
  • Lilly USA, LLC $61
$61 13 —
RYBELSUS
  • Novo Nordisk Inc $54
$54 — —
Ozempic
  • Novo Nordisk Inc $54
$54 86 —
Wegovy
  • Novo Nordisk Inc $54
$54 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

513 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record